Significant variations exist when comparing cancer treatment systems in the United States and Europe. The US model, generally characterized by for-profit insurance and a focus on innovation, often leads to early adoption of new therapies, albeit at a significantly increased cost. On the other hand, European systems frequently depend on public fundi